Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986504 plus nab-paclitaxel and gemcitabine in MTAP-deleted metastatic pancreatic ductal adenocarcinoma
jRCT2031250751Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of MRTX1719 in pancreatic adenocarcinoma (PDAC) (6 arms), sponsored by Bristol Myers Squibb. Started Mar 2026; status: recruiting.
02
Drugs
MRTX1719
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031250751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250751.